Cargando…

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma

BACKGROUND: The endothelin system is involved in tumour growth. Atrasentan, a selective endothelin-A-receptor antagonist, blocks endothelin signalling. This phase I trial studied combining treatment of interferon-alpha (IFN-α) with atrasentan in renal cell carcinoma (RCC). PATIENTS AND METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groenewegen, G, Walraven, M, Vermaat, J, de Gast, B, Witteveen, E, Giles, R, Haanen, J, Voest, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261664/ https://www.ncbi.nlm.nih.gov/pubmed/22215065 http://dx.doi.org/10.1038/bjc.2011.515

Ejemplares similares

Endothelin A Receptor Antagonist, Atrasentan, Attenuates Renal and Cardiac Dysfunction in Dahl Salt-Hypertensive Rats in a Blood Pressure Independent Manner
por: Samad, Mohammed A., et al.
Publicado: (2015)

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
por: Smeijer, J. David, et al.
Publicado: (2023)

Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats
por: Ritter, Cynthia, et al.
Publicado: (2014)

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
por: Koomen, Jeroen V., et al.
Publicado: (2018)

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
por: Verra, N, et al.
Publicado: (2003)

Reduced cilia frequencies in human renal cell carcinomas versus neighboring parenchymal tissue
por: Basten, Sander G, et al.
Publicado: (2013)

Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy
por: Kang, Wen-Ling, et al.
Publicado: (2016)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review
por: Walraven, Maudy, et al.
Publicado: (2010)

Corrigendum: Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy
por: Kang, Wen-Ling, et al.
Publicado: (2018)

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Webb, David J., et al.
Publicado: (2017)

Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease
por: Smeijer, J. David, et al.
Publicado: (2022)

Investigating the specificity of endothelin-traps as a potential therapeutic tool for endothelin-1 related disorders
por: Jain, Arjun, et al.
Publicado: (2022)

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2008)

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
por: Gore, M E, et al.
Publicado: (2015)

Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Koomen, Jeroen V., et al.
Publicado: (2021)

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
por: Unger, Joseph M., et al.
Publicado: (2018)

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2011)

Sleeve gastrectomy ameliorates endothelial function and prevents lung cancer by normalizing endothelin-1 axis in obese and diabetic rats
por: Ruze, Rexiati, et al.
Publicado: (2020)

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Sunitinib-induced cardiac hypertrophy and the endothelin axis
por: Sourdon, Joevin, et al.
Publicado: (2021)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

Endothelin
por: Davenport, Anthony P., et al.
Publicado: (2016)

Antigenic modulation of metastatic breast and ovary carcinoma cells by intracavitary injection of IFN-alpha.
por: Giacomini, P., et al.
Publicado: (1992)

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)

Elevated plasma levels of endothelin are associated with the severity of sepsis and presence of shock in contrast to the levels of atrial natriuretic peptide
por: Beishuizen, A., et al.
Publicado: (1992)

Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence
por: Morris, C D, et al.
Publicado: (2005)

Targeting the endothelin axis as a therapeutic strategy for oral cancer metastasis and pain
por: Dang, Dongmin, et al.
Publicado: (2020)

T cells upon activation promote endothelin 1 production in monocytes via IFN-γ and TNF-α
por: Shinagawa, Shoshi, et al.
Publicado: (2017)

Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)—a multicentre randomised controlled trial protocol
por: Chiquet, Christophe, et al.
Publicado: (2022)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Increased Endothelin-1 Levels of BAL Fluid in Patients with Behçet's Disease
por: Hamzaoui, Kamel, et al.
Publicado: (2007)

Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma
por: de Gast, G C, et al.
Publicado: (2003)

Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.
por: Hersey, P., et al.
Publicado: (1985)

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
por: Johnston, S. R., et al.
Publicado: (1998)

Endothelin-1 activation in pediatric patients undergoing surgical coarctation of the aorta repair
por: Frank, Benjamin Steven, et al.
Publicado: (2017)

Endothelin-1 Single Nucleotide Polymorphisms and Risk of Pulmonary Metastatic Osteosarcoma
por: Zang, Xiaofang, et al.
Publicado: (2013)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vi2tikutt7ig46m2hbf2jh0ug0